The Solid Tumor team at Knight Diagnostic Laboratories performs diagnostic and clinically actionable tests developed at Oregon Health and Science University. The department includes a variety of molecular platforms which allow testing to be developed using the most appropriate technology for the application. Testing includes high resolution melting curve (HRM) analyses which are fast and cost-effective for screening oncogene mutations, pyrosequencing, and Sanger sequencing using LNA-clamps for detecting mutations with high sensitivity (1% mutant allele).
Our mass spectroscopy-based solid tumor panel (SequenomR platform) covers 643 mutations across 53 genes known to be important in cancer, one of the largest cancer gene mutation panels available in the U.S.A. Positive results from these assays are confirmed by traditional Sanger sequencing. In addition, we have recently introduced our GeneTrailsTM 38 Cancer Gene Panel on the Ion Torrent PGMTM. More custom panels are in development and will be clinically available in the near future.
Targeted panels are available for the following tumor types:
Non-Small Cell Lung Cancer:
GI Stromal Tumor (GIST):
Endometrial Cancer (Endometrioid type)